EyeVerify enters new European market with Vodafone deal
June 9, 2015 | Bobby Burch
Biometrics tech company EyeVerify is continuing its global expansion into Europe with a new deal.
The Kansas City-based firm recently announced a licensing and marketing agreement with Turkish security tech company Olcsan CAD. The deal makes Olcsan the exclusive distributor of EyeVerify’s eye vein biometrics technology, or Eyeprint ID, throughout Turkey.
“We’re pleased to partner with Olcsan on both the technical and business aspects of delivering biometric solutions to Olcsan’s customers,” EyeVerify CEO Toby Rush said in a release. “Their expertise in implementation across numerous vertical markets will be invaluable in generating marketing adoption for Eyeprint ID.”
Already the partnership has yielded its first joint customer deal with Vodafone Turkey. Vodafone’s mobile wallet app Vodafone Cep Cüzdan now allows customers to register their Eyeprint with the app to login without a password.
EyeVerify in March scored a deal with ZTE — one of the largest phone manufacturers in the world — that placed its Eyeprint ID on the company’s flagship phone. The Eyeprint ID is now a default feature on the ZTE Grand S3. Located in Kansas City’s Crossroads Art District, EyeVerify has raised about $10 million to date.
Featured Business
2015 Startups to Watch
stats here
Related Posts on Startland News
In time for Mother’s Day: Ovatemp wants to boost women’s fertility
The arrival of Ana Mayer’s baby girl isn’t the only thing she’ll be thinking about this Mother’s Day. Mayer — who’s among the newest founders in the Techstars-led Sprint Mobile Health Accelerator in Kansas City — will also be mulling how to further develop Ovatemp, the Boston-based ovulation tech company she leads. Ovatemp offers women…
Founder of defunct Symptomly shares lessons from failure
Failure is a touchy subject. But for Derek Bereit — the former CEO and co-founder of mobile asthma tracking company Symptomly — his company’s failure was an opportunity shrouded in a difficult situation. Rather than sulking, Bereit sat down with Startland News to discuss Symptomly’s demise, the lessons it provided him and the possibilities that…